相关实验视频
Updated: May 6, 2026

08:33
An Ex vivo Culture System to Study Thyroid Development
Published on: June 6, 2014
12.0K
在甲状腺风暴与脑病的双过等离子体:一个案例报告
Qisheng Lin1, Haijiao Jin1, Yao Xu1
1Department of Nephrology, Ren Ji Hospital, Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Journal of clinical apheresis
|October 17, 2025
概括
甲状腺风暴是一个关键的内分泌紧急情况. 双过等离子体 (DFPP) 有效地治疗了患有甲状腺风暴和脑病变的患者,当标准治疗禁用时,改善了抗体和激素水平.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
背景情况:
- 甲状腺风暴是一种严重的内分泌紧急情况,死亡率高.
- 标准治疗方法 (抗甲状腺药物,β抑制剂,葡萄糖类皮质激素) 可能不足或禁用.
- 像等离子体合成这样的血液净化疗法是耐火病例的替代方案.
研究的目的:
- 报告使用双过等离子法 (DFPP) 治疗甲状腺风暴与甲状腺毒性脑病变的第一个病例.
- 评估DFPP在患有格雷夫斯病的患者的疗效和安全性,以及抗甲状腺药物的禁忌.
主要方法:
- 一名38岁的女性患有格雷夫斯病和甲状腺风暴 (Burch-Wartofsky得分70) 呈现脑病变和白血病.
- 由于抗甲状腺药物的禁忌,该患者接受了三次DFPP治疗.
- 通过监测抗thyrotropin受体抗体 (TRAb) 和自由甲状腺素 (FT4) 水平以及神经状态来评估治疗的疗效.
主要成果:
- 在DFPP之后,TRAb水平从>40降至29.8 IU/L,FT4水平从88.7降至19.7 pmol/L.
- 患者的意识显著改善,并解决了发作.
- DFPP可以选择性地去除大分子抗体,最大限度地减少血液产品和白蛋白损失.
结论:
- 双过等离子酶 (DFPP) 是甲状腺风暴的潜在有效和安全的血液净化疗法,特别是当抗甲状腺药物禁用时.
- DFPP迅速降低甲状腺激素和自身抗体,为严重病例提供了有价值的选择.
- 需要进行进一步的研究,以建立甲状腺风暴管理中等离子体酶的最佳协议.
相关概念视频
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
385
Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
385
Hyperthyroidism I: Introduction
64
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
64
Hyperthyroidism II: Pathophysiology
58
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
58
Graves' Disease I: Introduction
52
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
52
Graves Disease II: Pathophysiology
59
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
59
Hepatic Encephalopathy
71
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71

